<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01322971</url>
  </required_header>
  <id_info>
    <org_study_id>SU-03212011-7604</org_study_id>
    <secondary_id>IRB Protocol Number 20103</secondary_id>
    <nct_id>NCT01322971</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Preconception Treatment of an Asymptomatic Bacterial Infection in an Infertility Population</brief_title>
  <official_title>Pregnancy Outcomes Following Preconception Treatment of Asymptomatic Bacterial Vaginosis in an Infertility Population: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bacterial vaginosis (BV) is a common vaginal infection characterized by a pathologic shift in
      the normal vaginal flora. BV has been associated with a number of poor reproductive outcomes,
      including infertility, preterm labor and premature rupture of membranes. If BV does disrupt
      normal embryologic development, then the treatment of BV prior to conception may improve
      implantation rates and other pregnancy outcomes in the infertile population.

      This is a prospective, randomized, double-blind, placebo-controlled trial in which infertile
      women undergoing intrauterine insemination or embryo transfer are screened for BV prior to
      treatment. Those patients who screen positive for BV will then be randomized into the
      treatment arm(metronidazole 500mg by mouth twice daily for 7 days) or the control arm
      (placebo by mouth twice daily for 7 days). The primary outcome, positive pregnancy test rate
      (i.e. biochemical pregnancy rate), will then be assessed. Secondary outcomes, such as
      clinical pregnancy rate, miscarriage rate, and live birth rate will also be examined.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine if preconception treatment of asymptomatic
      bacterial vaginosis improves pregnancy outcomes (i.e. biochemical pregnancy rate). Study
      protocol as follows:

        1. Patients will be notified of study via face-to-face contact at the initial clinic visit
           (baseline ultrasound visit, menstrual cycle day 2-5), by physician referral or the
           Stanford website. Patients expressing interest will be screened in person to confirm
           that they meet all enrollment criteria. The participant will be asked to sign informed
           consent documents and a brief intake questionnaire with then be administered.

        2. Enrolled patients will then be screened for bacterial vaginosis at their next visit
           (typically on menstrual cycle day 12), prior to transvaginal ultrasound. The screening
           will require that a speculum be inserted into the vagina and a vaginal smear be
           collected with a swab from the posterior fornix. A microscopic slide will be prepared by
           rolling the swab on the surface of a glass slide. The diagnosis of bacterial vaginosis
           will be established clinically using the Amsel criteria to confirm 3 of the following 4
           signs: clue cells; vaginal pH â‰¥4.5; fishy odor before or after the addition of 10%
           potassium hydroxide solution to a wet-mount side; and a homogeneous, off-white,
           discharge. For validation of clinical diagnosis, 100% of screen positive slides, and 10%
           of screen negative slides, will be sent for to the Department of Pathology for Gram
           staining.

        3. The patients with a positive screen for bacterial vaginosis will then be randomized to
           receive metronidazole 500mg orally twice daily for seven days (treatment arm) or placebo
           orally twice daily for seven days(control arm). Randomization will be performed using a
           computer-generated code. Those patients whose screen is negative will also be followed
           for outcomes, but no randomization will be performed.

        4. All randomized patients will continue with routine monitoring and insemination as
           planned by their treating physician.

        5. If pregnancy is confirmed at least 12 weeks after intrauterine insemination by
           ultrasound evidence of a fetus with heartbeat, information will then be collected
           regarding the pregnancy and its outcome.

        6. Primary and secondary outcomes will be followed for 2 years after date of enrollment for
           all patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Disease prevalence lower than expected in population.
  </why_stopped>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical Pregnancy Rate (Positive Pregnancy Test)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Biochemical pregnancy rate was defined as number of participants who had a positive pregnancy test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy Rate (Pregnancy Visible on Ultrasound)</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage Rate (Loss of a Clinically Recognized Pregnancy)</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious Morbidity (i.e. Chorioamnionitis, Neonatal Sepsis)</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Vaginosis, Bacterial</condition>
  <condition>Infertility</condition>
  <condition>Miscarriage</condition>
  <arm_group>
    <arm_group_label>Metronidazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the metronidazole arm will receive metronidazole 500mg orally twice daily for seven days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized to the placebo arm will receive placebo orally twice daily for seven days(control arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Metronidazole 500mg orally twice daily for seven days</description>
    <arm_group_label>Metronidazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered orally twice daily for seven days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women who are actively trying to conceive via intrauterine insemination or in vitro
             fertilization

        Exclusion Criteria:

          -  Current use of an oral or vaginal antibiotic.

          -  History of allergy or adverse reaction to metronidazole.

          -  Prior enrollment in study (patients returning for repeat cycle may not be
             re-enrolled).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruth Bunker Lathi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruth Lathi</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Assessment of risk factors for preterm birth. Clinical management guidelines for obstetrician-gynecologists. Number 31, October 2001. (Replaces Technical Bulletin number 206, June 1995; Committee Opinion number 172, May 1996; Committee Opinion number 187, September 1997; Committee Opinion number 198, February 1998; and Committee Opinion number 251, January 2001). Obstet Gynecol. 2001 Oct;98(4):709-16.</citation>
    <PMID>11592272</PMID>
  </reference>
  <reference>
    <citation>Carey JC, Klebanoff MA, Hauth JC, Hillier SL, Thom EA, Ernest JM, Heine RP, Nugent RP, Fischer ML, Leveno KJ, Wapner R, Varner M. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 2000 Feb 24;342(8):534-40.</citation>
    <PMID>10684911</PMID>
  </reference>
  <reference>
    <citation>Donders GG, Van Bulck B, Caudron J, Londers L, Vereecken A, Spitz B. Relationship of bacterial vaginosis and mycoplasmas to the risk of spontaneous abortion. Am J Obstet Gynecol. 2000 Aug;183(2):431-7.</citation>
    <PMID>10942482</PMID>
  </reference>
  <reference>
    <citation>Hay PE, Lamont RF, Taylor-Robinson D, Morgan DJ, Ison C, Pearson J. Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. BMJ. 1994 Jan 29;308(6924):295-8.</citation>
    <PMID>8124116</PMID>
  </reference>
  <reference>
    <citation>Hay PE. Bacterial vaginosis and miscarriage. Curr Opin Infect Dis. 2004 Feb;17(1):41-4. Review.</citation>
    <PMID>15090889</PMID>
  </reference>
  <reference>
    <citation>Hillier SL, Nugent RP, Eschenbach DA, Krohn MA, Gibbs RS, Martin DH, Cotch MF, Edelman R, Pastorek JG 2nd, Rao AV, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N Engl J Med. 1995 Dec 28;333(26):1737-42.</citation>
    <PMID>7491137</PMID>
  </reference>
  <reference>
    <citation>Korn AP, Bolan G, Padian N, Ohm-Smith M, Schachter J, Landers DV. Plasma cell endometritis in women with symptomatic bacterial vaginosis. Obstet Gynecol. 1995 Mar;85(3):387-90.</citation>
    <PMID>7862377</PMID>
  </reference>
  <reference>
    <citation>Liversedge NH, Turner A, Horner PJ, Keay SD, Jenkins JM, Hull MG. The influence of bacterial vaginosis on in-vitro fertilization and embryo implantation during assisted reproduction treatment. Hum Reprod. 1999 Sep;14(9):2411-5.</citation>
    <PMID>10469722</PMID>
  </reference>
  <reference>
    <citation>McDonald HM, Brocklehurst P, Gordon A. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD000262. Review. Update in: Cochrane Database Syst Rev. 2013;1:CD000262.</citation>
    <PMID>17253447</PMID>
  </reference>
  <reference>
    <citation>Nelson DB, Bellamy S, Nachamkin I, Ness RB, Macones GA, Allen-Taylor L. First trimester bacterial vaginosis, individual microorganism levels, and risk of second trimester pregnancy loss among urban women. Fertil Steril. 2007 Nov;88(5):1396-403. Epub 2007 Apr 16.</citation>
    <PMID>17434499</PMID>
  </reference>
  <reference>
    <citation>Platz-Christensen JJ, Brandberg A, Wiqvist N. Increased prostaglandin concentrations in the cervical mucus of pregnant women with bacterial vaginosis. Prostaglandins. 1992 Feb;43(2):133-4.</citation>
    <PMID>1542740</PMID>
  </reference>
  <reference>
    <citation>Platz-Christensen JJ, Mattsby-Baltzer I, Thomsen P, Wiqvist N. Endotoxin and interleukin-1 alpha in the cervical mucus and vaginal fluid of pregnant women with bacterial vaginosis. Am J Obstet Gynecol. 1993 Nov;169(5):1161-6.</citation>
    <PMID>8238178</PMID>
  </reference>
  <reference>
    <citation>Wilson JD, Ralph SG, Rutherford AJ. Rates of bacterial vaginosis in women undergoing in vitro fertilisation for different types of infertility. BJOG. 2002 Jun;109(6):714-7.</citation>
    <PMID>12118653</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2011</study_first_submitted>
  <study_first_submitted_qc>March 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2011</study_first_posted>
  <results_first_submitted>October 26, 2016</results_first_submitted>
  <results_first_submitted_qc>November 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 20, 2017</results_first_posted>
  <last_update_submitted>November 23, 2016</last_update_submitted>
  <last_update_submitted_qc>November 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Ruth Bunker Lathi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Bacterial Vaginosis</keyword>
  <keyword>Infertility</keyword>
  <keyword>Miscarriage</keyword>
  <keyword>Metronidazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Abortion, Spontaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>151 participants were screened ; 2 were randomized</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Metronidazole</title>
          <description>Patients randomized to the metronidazole arm will receive metronidazole 500mg orally twice daily for seven days.
Metronidazole: Metronidazole 500mg orally twice daily for seven days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients randomized to the placebo arm will receive placebo orally twice daily for seven days(control arm
Placebo: Placebo will be administered orally twice daily for seven days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metronidazole</title>
          <description>Patients randomized to the metronidazole arm will receive metronidazole 500mg orally twice daily for seven days.
Metronidazole: Metronidazole 500mg orally twice daily for seven days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patients randomized to the placebo arm will receive placebo orally twice daily for seven days(control arm
Placebo: Placebo will be administered orally twice daily for seven days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" spread="0"/>
                    <measurement group_id="B2" value="37" spread="0"/>
                    <measurement group_id="B3" value="37" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Biochemical Pregnancy Rate (Positive Pregnancy Test)</title>
        <description>Biochemical pregnancy rate was defined as number of participants who had a positive pregnancy test</description>
        <time_frame>up to 2 years</time_frame>
        <population>No data were collected for this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Metronidazole</title>
            <description>Patients randomized to the metronidazole arm will receive metronidazole 500mg orally twice daily for seven days.
Metronidazole: Metronidazole 500mg orally twice daily for seven days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients randomized to the placebo arm will receive placebo orally twice daily for seven days(control arm
Placebo: Placebo will be administered orally twice daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Pregnancy Rate (Positive Pregnancy Test)</title>
          <description>Biochemical pregnancy rate was defined as number of participants who had a positive pregnancy test</description>
          <population>No data were collected for this outcome</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pregnancy Rate (Pregnancy Visible on Ultrasound)</title>
        <time_frame>up to 2 years</time_frame>
        <population>No data were collected for this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Metronidazole</title>
            <description>Patients randomized to the metronidazole arm will receive metronidazole 500mg orally twice daily for seven days.
Metronidazole: Metronidazole 500mg orally twice daily for seven days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients randomized to the placebo arm will receive placebo orally twice daily for seven days(control arm
Placebo: Placebo will be administered orally twice daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>Pregnancy Rate (Pregnancy Visible on Ultrasound)</title>
          <population>No data were collected for this outcome</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Miscarriage Rate (Loss of a Clinically Recognized Pregnancy)</title>
        <time_frame>up to 2 years</time_frame>
        <population>No data were collected for this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Metronidazole</title>
            <description>Patients randomized to the metronidazole arm will receive metronidazole 500mg orally twice daily for seven days.
Metronidazole: Metronidazole 500mg orally twice daily for seven days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients randomized to the placebo arm will receive placebo orally twice daily for seven days(control arm
Placebo: Placebo will be administered orally twice daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>Miscarriage Rate (Loss of a Clinically Recognized Pregnancy)</title>
          <population>No data were collected for this outcome</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infectious Morbidity (i.e. Chorioamnionitis, Neonatal Sepsis)</title>
        <time_frame>up to 2 years</time_frame>
        <population>No data were collected for this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Metronidazole</title>
            <description>Patients randomized to the metronidazole arm will receive metronidazole 500mg orally twice daily for seven days.
Metronidazole: Metronidazole 500mg orally twice daily for seven days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients randomized to the placebo arm will receive placebo orally twice daily for seven days(control arm
Placebo: Placebo will be administered orally twice daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>Infectious Morbidity (i.e. Chorioamnionitis, Neonatal Sepsis)</title>
          <population>No data were collected for this outcome</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All participants withdrew prior to entering any protocol specified adverse event collection period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Metronidazole</title>
          <description>Patients randomized to the metronidazole arm will receive metronidazole 500mg orally twice daily for seven days.
Metronidazole: Metronidazole 500mg orally twice daily for seven days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients randomized to the placebo arm will receive placebo orally twice daily for seven days(control arm
Placebo: Placebo will be administered orally twice daily for seven days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>151 screened 2 were randomized both refused to take medication not knowing if it were placebo or drug</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ruth Lathi</name_or_title>
      <organization>Stanford University</organization>
      <email>rlathi@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

